Annabel Samimy

Catherine Novack

Danielle Brill

Dev Prasad

Ritu Baral

Ryan Deschner

Sam Slutsky

Whitney Ijem

- Palvella Therapeutics, Inc. (PVLA) announced anticipated top-line data for its QTORIN 3.9% rapamycin anhydrous gel, including **Phase 3 data in microcystic lymphatic malformations (mLMs) in Q1 2026** and **Phase 2 data in cutaneous venous malformations (cVMs) in December 2025**.  **[1583648_0001104659-25-086685_tm2525080d1_ex99-1.htm:5]** 
- The company expects to announce a **third clinical indication for QTORIN rapamycin in September 2025** and a **new QTORIN program in Q4 2025**.  **[1583648_0001104659-25-086685_tm2525080d1_ex99-1.htm:4]** **[1583648_0001104659-25-086685_tm2525080d1_ex99-1.htm:5]** 
- PVLA reported a cash position of **$70.4 million as of June 30, 2025**, with a projected cash balance of **~$55 million at year-end**, providing a runway into **2H 2027**.   
- The company has made key leadership hires, including **Ashley Kline as Chief Commercial Officer in May 2025** and **David Osborne, Ph.D. as Chief Innovation Officer in September 2025**.  **[1583648_0001104659-25-086685_tm2525080d1_ex99-1.htm:3]**

PALVELLA THERAPEUTICS (PVLA)